Company Overview
Company Type: Public Company
Website: www.tetrabiopharma.com
Number of Employees: 33
Ticker: TBPM.Q (OTCPK)
Year Founded: -


Business Description
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
0.9
EBITDA
(12.2)
Total Enterprise Value
2.1
TEV/EBITDA
NM
EBIT
(12.3)
Cash & ST Invst.
0.5
P/Diluted EPS Before Extra
NM
Net Income
(39.0)
Total Debt
1.7
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
3.0
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Aug-31-2022 TEV and Market Cap are calculated using a close price as of Oct-05-2023

Key Professionals
Name
Title
Chamberland, Guy 
Co-Founder, CEO, Chief Regulatory Officer & Director
Rancourt, André 
Co-Founder
Auld, Leslie 
Chief Financial Officer
McCaughey, Jennifer 
Vice President of Investor Relations
Néron, Steeve 
Chief Commercial Officer
Pauw, Aurelia De
Senior VP of Clinical Programs & Medical Affairs
Scott, Dania 
Senior Vice President of Commercial Strategy
Giguere, Richard 
Chief Executive Officer of Tetra Natural Health Inc.
MacLean, Chris 
Chief Operating Officer of Tetra Natural Health
Ringuette, Randy 
Project Director & Member of Advisory Board

Key Board Members
Name
Title
Norton, Brent Henry-Barry
Independent Chairman
Chamberland, Guy 
Co-Founder, CEO, Chief Regulatory Officer & Director
Ringuette, Randy 
Project Director & Member of Advisory Board
Auld, Catherine 
Independent Director
Kim, John M.
Independent Director
Campbell, Charles 
Member of Advisory Board
Cullen, Cheryl
Member of Clinical Advisory Board
de Lorimier, Louis-Philippe
Member of Clinical Advisory Board
Edgett, Steven R.
Member of  Strategic Advisor
Greenblatt, Adam 
Member of Advisory Board
Prosk, Erin 
Member of Advisory Board
Webb, Aubrey
Member of Clinical Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
2316 St. Joseph Boulevard | Orléans, ON | K1C 1E8 | Canada

Current and Pending Investors
Alpha Blue Ocean Advisors Ltd (Pending), Alumina Partners LLC, Cannvalate PTY LTD, Echelon Wealth Partners Inc., Tilray Brands, Inc. (NasdaqGS:TLRY)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.0007
Market Cap (mm)
0.4
Open
 0.0011
Shares Out. (mm)
515.6
Previous Close
 0.0007
Float %
98.9%
Change on Day
0.00
Shares Sold Short (mm)
0.0
Change % on Day
(58.3)%
Dividend Yield %
-
Day High/Low
 0.0011/ 0.0005
Diluted EPS Excl. Extra Items
(0.09)
52 wk High/Low
 0.14/ 0.0001
P/Diluted EPS Before Extra
NM
Volume (mm)
0.99
Avg 3M Dly Vlm (mm)
0.39
Beta 5Y
1.88


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Panag Pharma Inc.
Panag Pharma Inc. develops bio pharmaceuticals and natural health products containing cannabis and other medicinal plant based elements. The company was founded in 2014 and is based in Halifax, Canada. As of May 1, 2019, Panag Pharma Inc. operates as a subsidiary of Tetra Bio-Pharma Inc.

United States and Canada
Pharmaceuticals
-
-
-
PhytoPain Pharma Inc.
PhytoPain Pharma Inc. manufactures cannabinoid-based drugs. The company was founded in 2016 and is based in Orleans, Canada. PhytoPain Pharma Inc. operates as a subsidiary of Tetra Bio-Pharma Inc.

United States and Canada
Pharmaceuticals
-
-
-
Laboratoires Holizen Inc.
Laboratoires Holizen Inc. produces and distributes therapeutic products. The company offers Miviton products that are nutritional tonics for mental and physical spheres; capsules, liquids, plant elixirs, and care products; Ayurvedic oils and herbal supplements; environmentally-friendly tote handles; VitaSil that are silicon based supplies for daily wellbeing; Omega-3, fish oil to maintain/sustain cardio vascular health; and herbal analgesic for chronic cutaneous diseases, and herbal sleep aids. It offers products through local dealers and online stores, as well as online. The company was founded in 2002 and is based in Saint-Hubert, Canada. As of June 22, 2016, Laboratoires Holizen Inc. operates as a subsidiary of GrowPros Cannabis Ventures Inc.

United States and Canada
Personal Care Products
-
-
-
Mazorro Resources Inc.
As of December 29, 2014, Mazorro Resources Inc. was acquired by GrowPros Cannabis Ventures Inc. in a reverse merger trasnaction. GrowPros Cannabis Ventures Inc., an exploration stage junior mining company, engages in the identification, acquisition, evaluation, and exploration of mineral properties. It primarily focuses on the exploration of gold properties in Quebec, Canada. The company has an option agreement to acquire a 100% interest in Dalquier property that includes 85 claims covering an area of 3,500 hectares located in the township of Dalquier, Quebec; and an option agreement to own a 75% interest in the Figuery property comprising 55 claims located in the Figuery, Landrienne, and Duverny Townships of Quebec. It also has an option agreement to earn a 70% interest in the Lapaska property consisting of 26 claims covering an area of approximately 352 hectares located in the Louvicourt Township of Quebec. The company was formerly known as Mazorro Resources Inc. and changed its name to GrowPros Cannabis Ventures Inc. in January 2015. GrowPros Cannabis Ventures Inc. was incorporated in 2007 and is based in Manotick, Canada.

United States and Canada
Gold
-
0.00
0.00
Synergy Acquisition Corp., Monster Lake Area Property
Synergy Acquisition Corp., Monster Lake Area Property comprises 81 mining claims spread over an area of 4,300 hectares. The property is located in Quebec, Canada.

United States and Canada
Diversified Metals and Mining
-
-
-
Agro-Tek Health Inc

United States and Canada
-
-
-
-
Agro-Tek Inc.
Agro-Tek Inc. manufactures and offers supplements, food-type products, and natural health products. The company is based in the United States. Agro-Tek Inc. operates as a subsidiary of Tetra Bio-Pharma Inc.

United States and Canada
Personal Care Products
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-11-2022
-
Private Placement
Target
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
Alpha Blue Ocean Advisors Ltd

7.84
May-05-2022
May-17-2022
Private Placement
Target
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
Cannvalate PTY LTD

0.38
Dec-1-2021
Dec-21-2021
Public Offering
Target
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)


1.65
May-28-2021
-
Public Offering
Target
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)


8.03
May-10-2021
May-17-2021
Public Offering
Target
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)


8.28
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-09-2023
Delistings
Tetra Bio-Pharma Common Shares to Delist from TSX Effective September 08, 2023
Mar-10-2023
Product-Related Announcements
Tetra Bio-Pharma Announces Health Canada Authorization to Proceed with its Oral ARDS-003 New Drug in Human Trial
Dec-22-2022
Product-Related Announcements
Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission
Dec-06-2022
Product-Related Announcements
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir
Nov-18-2022
Product-Related Announcements
Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

M&A Advisors
McGovern Hurley LLP, Paradigm Capital Inc.


Advisors
Most Recent Auditor
McGovern Hurley LLP
M&A Advisors
McGovern Hurley LLP, Paradigm Capital Inc.
Public Offering Advisors
McGovern Hurley LLP, Stikeman Elliott LLP


Most Recent Auditor
UHY McGovern Hurley LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:38 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_10_05
Reports
15
MarketLine

Sep 20, 2023 06:01 AM
TBPM.Q
Tetra Bio-Pharma Inc
Reports
36
S&P Global Compustat

Sep 07, 2023 03:42 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_09_07
Reports
15
S&P Global Compustat

Jul 06, 2023 03:20 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_07_06
Reports
15
S&P Global Compustat

Jun 01, 2023 04:05 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_06_01
Reports
15
S&P Global Compustat

May 04, 2023 03:41 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_05_04
Reports
15
S&P Global Compustat

Apr 06, 2023 03:56 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_04_06
Reports
15
S&P Global Compustat

Mar 02, 2023 03:33 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_03_02
Reports
15
S&P Global Compustat

Feb 02, 2023 03:19 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_02_02
Reports
15
S&P Global Compustat

Jan 05, 2023 03:45 AM
TBPM.Q
Tetra Bio Pharma Inc 2023_01_05
Reports
15


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Merton CA, CBV, CPA, Carl A.

4,815,436

0.93

0.0

Apr-18-2022


Kim, John M.

496,000

0.10

0.0

Apr-18-2022


Chamberland M.Sc., Master Herbal, Guy 

311,000

0.06

0.0

Apr-18-2022



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
ARDS-003 (Future), Caumz, Distribution of Soft Gel Capsules (Future), HCC011 (Future), PPP002 (Future), PPP005 (Future), QIXLEEF (Future), REDUVO (Future), Rx PrincepsTM Inhalation Device


Upcoming Events
Date/Time
Type
Oct-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
May-11-2023
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
154 KB
Mar-10-2023
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
178 KB
Mar-07-2023
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
127 KB
Mar-03-2023
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
196 KB
Mar-01-2023
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
148 KB
Feb-10-2023
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
43 KB
Dec-22-2022
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
32 KB
Dec-06-2022
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
74 KB
Nov-29-2022
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
74 KB
Nov-18-2022
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
43 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Kim, John M. (Independent Director)
Dec-21-2021
Class A Common Shares
350,000
60,352
Private Acquisition
239.73
Multiple
Néron, Steeve  (Chief Commercial Officer)
May-03-2021
Class A Common Shares
(50,000)
(26,851)
Open Market Disposition
(33.25)
Exchange Announcement
Néron, Steeve  (Chief Commercial Officer)
Apr-29-2021
Class A Common Shares
17,410
6,783
Other Acquisition
13.09
Exchange Announcement
Néron, Steeve  (Chief Commercial Officer)
Apr-29-2021
Class A Common Shares
62,860
14,694
Derivative Exercise and Retained Stock
71.83
Exchange Announcement
Néron, Steeve  (Chief Commercial Officer)
Apr-29-2021
Class A Common Shares
(17,140)
(2,671)
Derivative Exercise and Sale
-
Exchange Announcement
-
Apr-29-2021
Class A Common Shares
17,140
4,007
Derivative Exercise
-
Exchange Announcement
-
Apr-29-2021
Class A Common Shares
(17,140)
(6,678)
Sale
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Norton, Brent Henry-Barry
Independent Chairman
-
-
norton@orthorti.com
Chamberland, Guy 
Co-Founder, CEO, Chief Regulatory Officer & Director
514-220-9225
-
Guy@tetrabiopharma.com
Ringuette, Randy 
Project Director & Member of Advisory Board
-
-

Auld, Catherine 
Independent Director
-
-

Kim, John M.
Independent Director
-
-

Campbell, Charles 
Member of Advisory Board
-
-

Cullen, Cheryl
Member of Clinical Advisory Board
-
-
-
de Lorimier, Louis-Philippe
Member of Clinical Advisory Board
-
-
-
Edgett, Steven R.
Member of  Strategic Advisor
-
-

Greenblatt, Adam 
Member of Advisory Board
-
-

Prosk, Erin 
Member of Advisory Board
-
-

Webb, Aubrey
Member of Clinical Advisory Board
-
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Chamberland, Guy 
Co-Founder, CEO, Chief Regulatory Officer & Director
514-220-9225
-
Guy@tetrabiopharma.com
Rancourt, André 
Co-Founder
(438) 899-7575
-
andre.r@tetrabiopharma.com
Auld, Leslie 
Chief Financial Officer
-
-

McCaughey, Jennifer 
Vice President of Investor Relations
514-731-000 ext. 229
-
-
Néron, Steeve 
Chief Commercial Officer
-
-

Pauw, Aurelia De
Senior VP of Clinical Programs & Medical Affairs
-
-

Scott, Dania 
Senior Vice President of Commercial Strategy
-
-

Giguere, Richard 
Chief Executive Officer of Tetra Natural Health Inc.
-
-
rgiguere@tetranaturalhealth.com
MacLean, Chris 
Chief Operating Officer of Tetra Natural Health
-
-
-
Ringuette, Randy 
Project Director & Member of Advisory Board
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
